AHA 2022

Episodes 1-10 of 10

Long-term efficacy and safety of intravenous iron in HF
Long-term efficacy and safety of intravenous iron in HF
AHA 2022
Long-term efficacy and safety of intravenous iron in HF
Improved outcomes with rapid uptitration of HF medication after acute HF
Improved outcomes with rapid uptitration of HF medication after acute HF
AHA 2022
Improved outcomes with rapid uptitration of HF medication after acute HF
- Prof. Alexandre Mebazaa, MD, PhD
Low-dose statin lowers LDL-c more than dietary supplements
Low-dose statin lowers LDL-c more than dietary supplements
AHA 2022
Low-dose statin lowers LDL-c more than dietary supplements
- Luke J. Laffin, MD
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
AHA 2022
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
- Prof. Pamela Douglas, MD
Is one diuretic better than the other diuretic in veterans with hypertension?
Is one diuretic better than the other diuretic in veterans with hypertension?
AHA 2022
Is one diuretic better than the other diuretic in veterans with hypertension?
- Areef Ishani, MD
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
AHA 2022
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
- Robert J. Mentz, MD
Mindfulness-based BP-reduction program outperforms enhanced usual care
Mindfulness-based BP-reduction program outperforms enhanced usual care
AHA 2022
Mindfulness-based BP-reduction program outperforms enhanced usual care
- Eric Loucks, PhD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
AHA 2022
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
- David Preiss, PhD
First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
AHA 2022
First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
- Prof. Julian D. Gillmore, MD, PhD
Gene editing to treat transthyretin amyloidosis with cardiomyopathy
Gene editing to treat transthyretin amyloidosis with cardiomyopathy
AHA 2022
Gene editing to treat transthyretin amyloidosis with cardiomyopathy
- Kiran Musunuru, MD, PhD

Episodes 1-10 of 10

Title

Share on ReachMD